45 results about "Microalbuminuria" patented technology

The invention discloses a test strip for semi-quantitative detection of microalbuminuria, belonging to medical test consumables. The test strip is characterized in that the test strip for semi-quantitative detection of microalbuminuria is a colloidal gold test strip. An anti-human albumin antibody and rabbit IgG with acolloidal gold label is enveloped on a gold label fiber pad; anti-rabbit IgG antibody is enveloped on a quality control line C, and human albumin is enveloped on a detection line T. The test strip is simple, sensitive and accurate, can be used for semi-quantitative detection of microalbuminuria in human urine and suitable for detection of early renal injury patients.

The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a composition for the treatment of insulin resistance or diseases associated with insulin resistance, preferably in human subject in a daily dosage in a range of from about 5 mg to about 1500 mg. The invention furthermore relates to a method of treating insulin resistance or diseases associated with insulin resistance in a mammal, said method comprises administering to said mamma, preferably a human subject, a substance with the core structure of formula (I), preferably in a daily dosage in a range from about 5 mg to about 1500 mg. The substance is preferably isosteviol or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. Examples of diseases associated with insulin resistance are e.g. type 2 diabetes mellitus, insulin resistance syndrome, impaired glucose tolerance, the metabolic syndrome, hyperglycemia, hyperinsulinemia, arteriosclerosis, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, dyslipidemia, obesity, central obesity, polycystic ovarian syndrome, hypercoagulability, hypertension, microalbuminuria, or any combinations thereof.

The invention provides a kit for measuring microalbuminuria by adopting immune competition turbidimetry. The kit comprises an anti-human albumin antibody, human albumin marked leatexbeads and a buffersolution. The anti-human albumin antibody and the human albumin marked leatexbeads are separately placed. The particle size of the leatexbeads is 80-267 nm. When the kit is used for measuring microalbuminuria in human urine, the maximum linear range is 5 mg/L-1500 mg/L. The kit can meet screening of clinical normal people, and can also avoid result underestimation or even false negative result arising from a hook effect caused by antigen excess.

The invention provides a microalbuminuria (mAlb) detection kit, which is based on a latex enhanced turbidimetric immunoassay method, is a liquid double reagent, namely reagent R1 and reagent R2, wherein the reagent R1 is a reactant and the reagent R2 is a solution containing albumin immuno latex particles, and the detection kit is characterized by crosslinking by applying a chemical process, and covalently crosslinking a goat anti-human albumin antibody (also called goat anti-human mAlb antibody) with carboxylated polystyrene latex through water-soluble carbodiimide (EDC) and H-hydroxy succinimide (NHS), so as to form an mAlb antibody latex reagent. The reagent has the advantages of high sensitivity, strong specificity and simple preparation, and is worthy of further promotion.

The invention relates to a urinary microalbumin (U-mALb)/urinary creatinine (U-Cr) integrated assay bigeminy strip, comprising a sample area and reaction areas. The U-mALb/U-Cr integrated assay bigeminy strip is characterized in that the sample area comprises a diffusion membrane and blood filtering membranes; the reaction areas comprise two detection windows, and the two detection windows can be used for detecting the ratios of the U-mALb and the U-Cr at the same time; the sample area for detecting the U-Cr by adopting a dry chemical method is arranged at the position where the reaction area is positioned, and the reaction area for detecting the U-mALb by using a colloidal gold dry type immune chromatography technology is arranged at a position which is 0.5cm away from the sample area. The different reaction areas contain different reagent pads, and the reagent pads respectively and independently react with corresponding components in urine. Synchronous detection can be realized only by dripping the random urine of a person to be tested into the sample area, so that the U-mALb/U-Cr integrated assay bigeminy strip is very suitable for medical institutions or individuals. By using the U-Cr for correction, the influence, caused by a sampling way and urine volume, on the excretory amount of urinary albumin can be eliminated, so that the U-mALb/U-Cr integrated assay bigeminy strip can provide more accurate evaluation for the albumin excretion rate and has a greater clinical significance for preventing diabetic nephropathy.

The invention discloses a kit for determining microalbuminuria and a preparation method thereof. The kit comprises dual-liquid components of a reagent R1 and a reagent R2 which are independent from each other. The reagent R1 is prepared from a buffer solution, an accelerator, inorganic salt ions and a corrosion remover; the reagent R2 is prepared from a buffer solution, a suspending agent, a surface active agent, inorganic salt ions, a corrosion remover and anti-albumin antibodies, and a solvent of the reagent R2 is purified water. The preparation method comprises the steps that the reagents are prepared according to the component content; a to-be-tested sample is mixed with the reagent R1 and the reagent R2 to be subjected to a sufficient reaction; a fully automatic biochemical analyzer is used for determining an absorptivity difference obtained after the reaction; according to an absorptivity change value, the concentration of microalbuminuria in the sample is worked out. The kit has the advantages of being convenient to operate, high in accuracy and the like.

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and an oral antidiabetic agent for treating and/or preventing complications (including microalbuminuria, nephropathies, retinopathies and other complications) in patients with diabetes or metabolic syndrome.

The invention provides application of anhydroicaritin in preparation of drugs used for treatment or prevention of diabetes, which belongs to the field of medicine. Anhydroicaritin is a Chinese herbal monomer extracted from the traditional Chinese medicine epimedium; when used for treating a patient with diabetes, anhydroicaritin can substantially reduce the contents of fasting blood-glucose and 2-h postprandial blood sugar and substantially lower down the rate of glycosylated hemoglobin and the content of microalbuminuria, and anhydroicaritin has a better treatment effect compared with those of an epimedium extract treatment group and an icariin treatment group. Anhydroicaritin has the advantages of definite therapeutic effects, small side effects, capacity of alleviating occurrence of diabetic complications and wide medical application prospects when used for treatment of diabetes.

The invention discloses a medical new application of two halophenol compounds 4,5,2'-trihydroxy-2,5'-dibromobenzophenone and 4,5,2'-tri(4-morpholine methanoyl)-2,5'-dibromobenzophenone, in particular an application in preparation of medicines of resisting type II diabetic nephropathy. Meanwhile, the invention also discloses a medicine of resisting type II diabetic nephropathy employing the two halophenol compounds as active ingredients. By the two compounds, the renal function of the type II diabetic nephropathy can be effectively improved; the main treatment indexes, namely uric acid, urine protein, microalbuminuria, transforming growth factor TGF-beta1, blood sugar, low-density lipoprotein and the like are superior to those of an existing clinic first-line medicine captopril; and the important application prospect in treatment of the diabetic nephropathy is displayed.

The invention relates to a microalbuminuria and urine creatinine integrated test card, which comprises a backboard. A microalbuminuria detecting part and a urine creatinine detecting part are arrangedon the backboard and share one sample pad. Reacting areas and detecting areas of the microalbuminuria detecting part and the urine creatinine detecting part are located at the two ends of the samplepad correspondingly. The microalbuminuria and urine creatinine integrated test card has the advantages of being simple in preparation method, convenient to operate, quick and accurate in detecting andthe like.

The invention belongs to the technical field of traditional Chinese medicines, relates to a traditional Chinese medicinal composition and a preparation method thereof, and particularly relates to a traditional Chinese medicinal composition for treating diabetes mellitus and a preparation method thereof. Against existing technical defects, the traditional Chinese medicinal composition for treating or preventing diabetes mellitus comprises the following components in parts by weight: 10-20 parts radices trichosanthis, 5-20 parts of raw rehmmania root, 5-15 parts of astragalus membranaceus, 5-15 parts of kudzu vine root, 1-10 parts of dendrobium nobile, 9-15 parts of schisandra chinensis, 5-15 parts of salvia miltiorrhiza, 1.5-9 parts of radix ophiopogonis, 9-15 parts of poria and 5.5-15 parts of liquorice. The traditional Chinese medicinal composition can be used for remarkably improving symptoms of diabetes mellitus in the aspects of blood glucose, microalbuminuria and glycosylated hemoglobin of a diabetes rat.

The invention relates to new application and a new action mechanism of verbascoside, in particular to application of verbascoside in the drugs for treating and preventing type II diabetic nephropathy,and the research on the protection function of the verbascoside for the type II diabetic nephropathy and the action mechanism thereof. Results show that the verbascoside can alleviate liver injury caused by high glucose and lower the serum creatinine, urea nitrogen and urinary microalbuminuria levels, the blood fat level (total cholesterol and triglyceride) and the fasting blood-glucose and bloodinsulin level of spontaneous diabetes db/db mice; TGF (Transforming Growth Factor)-beta 1 and the signal transduction protein Smad3 and Smad4 and alpha-SMA protein expression thereof in a kidney tissue are obviously lowered; meanwhile, the verbascoside can alleviate the liver injury caused by high glucose; HK-2 proliferation and EMT (pithelial-Mesenchymal Transition) formation can be inhibited. In conclusion, the verbascoside has an obvious protection function on the type II diabetic nephropathy, the action mechanism of the verbascoside is that the kidney protection function of the verbascoside is implemented through oxidative stress reaction regulation and control, TGF-beta/smad signaling channel inhibition and kidney fibrosis alleviation.

The invention specifically relates to application of bupleurum polysaccharide in preparation of drugs used for preventing and treating diabetic nephropathy, which belongs to the field of traditional Chinese medicine. According to results of integral experiments and in-vitro experiments, bupleurum polysaccharide extract has obvious prevention and treatment effect on diabetic nephropathy. Bupleurum polysaccharide can improve the body weight of diseased animals, substantially reduce the level of blood sugar and urine sugar, obviously promote secretion of insulin, decrease the level of serum creatinine, reduce secretion level of microalbuminuria and the renal index and enhance renal pathological symptoms, thereby exerting blood sugar-reducing and kidney-protecting effect. Bupleurum polysaccharide can reverse tubular cell transdifferentiation causec by TGF-beta. The bupleurum polysaccharide can be used for preparation of drugs used for preventing and treating diabetes and renal complications caused by diabetes.

The invention provides a detection method for microalbuminuria (mAlb). The detection method for microalbuminuria is based on the latex-enhanced immunoturbidimetric assay, and adopts a liquid double reagent comprising a reagent R1 and a reagent R2, wherein the reagent R1 serves as a reactant; the reagent R2 is a solution containing albumin immuno-latex particles. The detection method is characterized by applying a chemical method for cross-linking and preparing an mAlb antibody latex reagent via covalent cross-linking between goat anti-human albumin antibody (also called as goat anti-human mAlb antibody) and carboxylated polystyrene by using water-soluble carbodiimide (EDC) and N-hydroxy succinimide (NHS). The mAlb antibody latex reagent is high in sensitivity and specificity, simple to prepare, and worth of further popularization and use.

The invention discloses treating diabetic nephropathy and microalbuminuria with Chinese herbal medicine Salviae Miltiorrhizae Radix. Including boiling salvia miltiorrhiza to make a water-based extract, and then applying the extract to diabetics or microalbuminuric patients to treat diabetic nephropathy. In addition, it also includes the use of succinic acid inorganic salt extracted from Danshen to the sick body. The present invention also includes measuring the protein level in urine before, during and/or after administering the water-based extract or the inorganic salt of succinic acid to the patient.

The invention relates to the technical field of biochemical detection, in particular to a test strip, a preparation method thereof and an application of the test strip to combined detection of microalbuminuria and beta2 microglobulin. According to the test strip, a sample pad, a gold mark pad, a chromatography membrane and absorbent paper are sequentially arranged on a bottom plate, and the gold mark pad and the chromatography membrane are coated with antibodies or antigens of specific content, so that detection limit of the test strip is effectively controlled and is a cut off value of albumin and the beta2 microglobulin. According to the test strip, the albumin and the beta2 microglobulin can be simultaneously detected by the aid of antibody concentration, and mutual interference is avoided. By the aid of the test strip, urine samples are directly detected, a pretreatment step is omitted, and detection of the test strip is rapider and more reliable. Experiments show that the test strip is high in accuracy, and the preparation method of the test strip is quite simple.

The invention provides a use of Rosaceae Malus plant or its extract in the preparation of insulin resistance improvement medicines. The invention also provides a medicinal composition for improving the insulin resistance. The medicine can improve the insulin resistance, can be used for preventing or/and treating insulin resistance syndromes, can be used in medicines for preventing or/and treating a group of clinic syndromes characterized by insulin resistance, comprising abnormal glucose metabolism, hypertension, lipid metabolism disorder, abdominal or visceral obesity, atherosclerosis, coronary heart disease, polycystic ovary syndrome, fibrinogen increase, fibrinolytic activity reduction, microalbuminuria, hyperuricemia and hyperleptinemia, and has clear medicine effects.

The invention relates to a bombyx mori extract, in particular to the bombyx mori extract and an extraction method and application thereof. The extraction method includes the steps that 5-old bombyx mori is taken and prepared into bombyx mori freeze-dried powder after freeze drying and smashing, after an alcohol-water solution is added, soaking, ultrasonic treatment and filtering are conducted, and filtrate A is obtained; 2, an alcohol-water solution is added to sediment obtained in the step 1, soaking, ultrasonic treatment and filtering are conducted, and filtrate B is obtained; 3, the filtrate A and the filtrate B are combined, vacuum concentration and drying are conducted, and then the bombyx mori extract is obtained. The bombyx mori extract can be applied to relieving insulin resistance and enhancing cell glucose uptake. On the aspect of relieving insulin resistance, the bombyx mori extract is applied to preparing medicine for treating or relieving insulin resistance syndromes and preparing medicine for treating type 2 diabetes, obesity, hypertension, dyslipidemia, polycystic ovarian syndromes, hyper blood-coagulation disorder, microalbuminuria and other diseases. On the aspect of enhancing cell glucose uptake, the bombyx mori extract is applied to preparing medicine for treating or relieving type 1 diabetes.

The invention relates to microalbuminuria immunogen, a preparation method of the microalbuminuria immunogen, a polyclonal antibody, a preparation method of the polyclonal antibody, a detection reagentand test paper. The preparation method of the microalbuminuria immunogen comprises the following steps: microalbuminuria in urine is purified; and the microalbuminuria is subjected to heat treatmentand cold treatment to be partially denatured, and the microalbuminuria immunogen is obtained, wherein the heat treatment temperature is 55-65 DEG C, and the cold treatment temperature is 0-5 DEG C. The polyclonal antibody obtained through immunization of the microalbuminuria immunogen has high accuracy in microalbuminuria detecting.

The invention discloses a traditional Chinese medicine composition for treating abnormal blood glucose and blood lipid due to diabetes mellitus. The composition is prepared from the following raw materials in parts by weight: 20-30 parts of rhizoma atractylodis, 10-15 parts of herba eupatorii, 8-15 parts of ginseng, 3-20 parts of kudzu vine roots, 15-30 parts of rhizoma polygonati, 12-15 parts of radix ophiopogonis, 12-18 parts of radix sophorae flavescentis, 12-20 parts of coptis chinensis, 15-25 parts of salviae miltiorrhizae, 20-25 parts of semen litchi, 10-20 parts of semen cuscutae, 10-18 parts of rhizoma alismatis, 12-30 parts of astragalus membranaceus, 10-15 parts of dried rehamnnia root, 10-15 parts of cornus officinalis, 10-15 parts of herba epimedii, 10-15 parts of cortex lycii radicis, 10-15 parts of red yeast rice and 10-15 parts of abelmoschus manihot. The invention further discloses a preparation method and an application range of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the effects of nourishing yin, promoting generation of body fluid, tonifying qi, nourishing kidneys, lowering blood glucose and blood lipid, protecting islet B cells of type 2 diabetic patients, reducing insulin resistance, improving insulin sensitivity, reversing renal lesions to a certain extent, improving microalbuminuria, reducing blood lipid and improving lipid metabolism, thereby solving the injury caused by abnormal blood glucose and blood lipid due to diabetes mellitus.

The invention discloses a novel pharmaceutical application of a potassium ATP channel regulator, namely application of the potassium ATP channel regulator (such as diazoxide, crocarine, pinadil, niacdil, alplecarine and the like) in preparation of a medicine for resisting diabetic nephropathy. The invention further provides application of a pharmaceutical composition taking the potassium ATP channel regulator as an active ingredient in prevention or treatment of diabetic nephropathy. A diabetic rat is modeled through streptozotocin (STZ), high fat diet is given to the rat after modeling to form the diabetic nephropathy, whether the rat enters the diabetic nephropathy or not is detected by taking microalbuminuria (mALB) as an index, and whether the model succeeds or not is observed by taking the weight and blood sugar level of the rat as indexes. Experimental results show that after the potassium ATP channel opener such as diazoxide is administered to the diabetic rat, the renal injury process of the diabetic rat can be delayed.